SCHEMBL1269735

SCHEMBL1269735

CCC(=O)c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ERCC5 P28715 1/20 0.64
FEN1 P39748 1/20 0.64
SMN1; SMN2 Q16637 4/20 0.63
MAPT P10636 2/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
MMP1 P03956 1/20 0.58
PARP10 Q53GL7 1/20 0.58
RAB9A P51151 3/20 0.58
ALDH1A1 P00352 2/20 0.58
NPC1 O15118 2/20 0.58
GAA P10253 1/20 0.58
HTT P42858 1/20 0.58
SRD5A2 P31213 3/20 0.56
HDAC3 O15379 1/20 0.53
LTA4H P09960 1/20 0.52
POLB P06746 1/20 0.51
HPGD P15428 1/20 0.50
CRHBP P24387 1/20 0.50
CRHR2 Q13324 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11052292 0.92 MAPT (0.58) ERCC5FEN1SMN1; SMN2MAPTL3MBTL1
SCHEMBL7860509 0.91 SMN1; SMN2 (0.79) ERCC5FEN1SMN1; SMN2MAPTL3MBTL1
SCHEMBL6032575 0.85 L3MBTL1 (0.66) ERCC5FEN1SMN1; SMN2MAPTL3MBTL1
SCHEMBL5279835 0.85 PKM (0.68) SMN1; SMN2MAPTL3MBTL1PARP10RAB9A
SCHEMBL6061938 0.85 PARP10 (0.58) SMN1; SMN2MAPTPARP10RAB9ANPC1
SCHEMBL11955348 0.85 KMT2A (0.64) MAPTMMP1PARP10RAB9AALDH1A1
SCHEMBL27504557 0.84 SMN1; SMN2 (0.53) ERCC5FEN1SMN1; SMN2MAPTL3MBTL1
SCHEMBL9814634 0.84 MMP1 (0.77) ERCC5FEN1SMN1; SMN2MAPTL3MBTL1
SCHEMBL10455392 0.84 ERCC5 (0.67) ERCC5FEN1SMN1; SMN2MAPTL3MBTL1
SCHEMBL6142809 0.83 MMP1 (0.59) SMN1; SMN2MAPTL3MBTL1MMP1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102341494-B Transaminase polypeptides CODEXIS, INC. (US) 2014-10-15 CN claimed
CN-102341494-A TRANSAMINASE POLYPEPTIDES CODEXIS INC 2012-02-01 CN claimed
EP-0003002-B1 USE OF AROMATIC-ALIPHATIC KETONES AS PHOTOINITIATORS, PHOTOPOLYMERISABLE SYSTEMS CONTAINING SUCH KETONES AND AROMATIC-ALIPHATIC KETONES CIBA-GEIGY AG (CH) 1984-06-13 EP claimed
WO-2020141439-A1 HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) 2020-07-09 WO disclosed
US-20200206233-A1 HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) 2020-07-02 US disclosed
US-20200206233-A1 HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) 2020-07-02 US disclosed
US-20190040269-A1 POWDER COMPOSITION OF POLYARYLENE ETHER KETONE KETONES ALLOWING AN EXCELLENT CASTABILITY/COALESCENCE BALANCE SUITABLE FOR LASER SINTERING ARKEMA FRANCE (FR) 2019-02-07 US disclosed
CN-108602818-A Pyrazole fused ring analog derivative, preparation method and its application in treating cancer, inflammation and immunity disease 北京诺诚健华医药科技有限公司 2018-09-28 CN disclosed
CN-107226805-A Aromatic amides analog derivative, its preparation method and its in application pharmaceutically 北京天诚医药科技有限公司 2017-10-03 CN disclosed
US-20170253696-A1 METHOD FOR MAKING POLYARYLALIPHATICETHERKETONE POLYMERS AND COPOLYMERS THEREOF OXFORD PERFORMANCE MATERIALS, INC 2017-09-07 US disclosed
CN-106588806-A Bromophenol-oxazole compound and its use in drug for treatment on diabetes mellitus type 2 中国科学院海洋研究所 2017-04-26 CN disclosed
EP-1638909-A2 PROCESS FOR PREPARING ALKOXY- AND ARYLOXY-PHENOLS ENDURA S.p.A. (IT) 2006-03-29 EP disclosed
WO-2004092106-A2 PROCESS FOR PREPARING ALKOXY- AND ARYLOXY-PHENOLS ENDURA S.P.A. (IT) 2004-10-28 WO disclosed
US-5266585-A Controlling phytopathogenic microorganisms, fungicides, antimycotics, anticonvulsives and/or anxiolytic agents CIBA-GEIGY CORPORATION (US) 1993-11-30 US disclosed
EP-0324472-B1 KETENEDITHIOACETAL DERIVATIVES AND PROCESSES FOR PRODUCING THE SAME AS WELL AS A COMPOSITION CONTAINING THE SAME NIHON NOHYAKU CO., LTD. (JP) 1992-09-02 EP disclosed
US-5098928-A Antilipemic agents and treatment of arteriosclerosis NIHON NOHYAKU CO., LTD. (JP) 1992-03-24 US disclosed
EP-0324472-A2 Ketenedithioacetal derivatives and processes for producing the same as well as a composition containing the same NIHON NOHYAKU CO., LTD. (JP) 1989-07-19 EP disclosed
EP-0112284-A2 Arylphenyl ether derivatives CIBA-GEIGY AG (CH) 1984-06-27 EP disclosed
EP-0009683-A1 Basic phenyl ethers, pharmaceutical compositions containing them and the preparation of these ethers and compositions MERCK PATENT GmbH (DE) 1980-04-16 EP disclosed
US-3932530-A ANTIINFLAMMATORY AGENTS SANDOZ, INC. (US) 1976-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200206233-A1 HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS IDH1, IDH2, IDH3A ERCC5 1551/4885FEN1 2562/4885SMN1; SMN2 1763/4885
US-20170253696-A1 METHOD FOR MAKING POLYARYLALIPHATICETHERKETONE POLYMERS AND COPOLYMERS THEREOF COASY, FRK, PBK ERCC5 2918/4885FEN1 3558/4885SMN1; SMN2 4677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.